C.L.E. Begins Shipping All PCA 2024 Exclusives

May 29, 2024 By Matthew Tabacco

C.L.E. Cigar Company announces that the annual PCA Exclusive blends are now shipping. In what has become a yearly tradition Christian Eiroa, and team presented the 2024 PCA Exclusive blends for C.L.E. Cigars, Eiroa Cigars, and Asylum Cigars at the 2024 PCA.

In Christian’s fourth installment of the PCA exclusive cigars, he wanted to showcase the different wrappers by creating a unique and innovative 100 count Honey-Comb display. These displays will not only be useful for the PCA exclusives but can remain in the stores as a permanent display for future CLE, EIROA or Asylum Cigars. 

The blends were each created using tobacco from C.L.E. Cigar Company’s farm in South America. The proprietary binder and filler of each [blend] was blended by Christian Eiroa. Each brand will feature a different wrapper.

Christian Eiroa President and Founder of C.L.E. Cigar Company stated: “We are slowly rolling out this tobacco from our South American farm. Last years’ PCA exclusives used tobacco from that farm, and it was well received. The tobacco has now gone through another year of aging, so the smoker can expect a more refined smoking experience. I am also excited to share this new and attractive box, which will house one hundred cigars.”

C.LE. 2024 PCA Exclusive: Connecticut wrapper

Eiroa 2024 PCA Exclusive: Maduro wrapper

Asylum 2024 PCA Exclusive: Habano wrapper

The three 2024 PCA Exclusive blends are offered in one hundred count boxes and will contain four different vitolas of the blends. Vitola: 50 x 5, 11 x 18, 52 x 6, 60 x 6    

MSRP $1,896.00 per 100 count box.

MSRP $18.96 per cigar.

Related Posts

Perdomo Hires Michael Giannini

January 24, 2025 By Matthew Tabacco
Today, Perdomo Cigars announced that Michael Giannini, a longtime executive and figure of the cigar industry, has joined their Sales & Marketing team. Read more
FDA Updates

Cigar Industry Scores Second Win Against FDA in Regulation Case

January 24, 2025 By Matthew Tabacco
Today, the United States Court of Appeals for the District of Columbia issued its decision in CAA et al. v. FDA. Read more